Cancer vaccine therapy using iPS-derived dendritic cells expressing TAA

2016 Fiscal Year Final Research Report

• Project/Area Number: 26461991
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Wakayama Medical University
• Principal Investigator: Ojima Toshiyasu 和歌山県立医科大学, 医学部, 講師 (60448785)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: iPS細胞 / 樹状細胞 / 腫瘍抗原 / ウイルスベクター / がんワクチン

Outline of Final Research Achievements

We investigated whether genetically modified human induced pluripotent stem cell (iPSC)-derived dendritic cells (hiPSDCs) expressing carcinoembryonic antigen (CEA) could induce CEA-specific cytotoxic T cells in a human model, and whether genetically modified mouse iPSDCs (miPSDCs) expressing CEA would show an actual antitumor effect using a CEA transgenic mouse model. We differentiated hiPSDCs from iPSCs of three healthy donors and transduced the CEA cDNA into hiPSDCs. The cytotoxic T cells induced by hiPSDCs-CEA exhibited CEA-specific cytotoxic activity against the target cells expressing CEA. Furthermore, in the CEA transgenic mouse model, the cytotoxic T cells generated in mice immunized with miPSDCs-CEA showed CEA-specific cytotoxic activity against MC38-CEA. Genetically modified iPSDCs expressing CEA is a promising tool for clinical application on vaccine therapy against gastrointestinal cancer patients.

Free Research Field

腫瘍免疫学